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1102-22 Persistently Elevated Levels of Soluble CD40 Ligand 
One Month After Percutaneous Coronary Angioplasty 
Correlate With Six-Month Restenosis 
&&g@ I CAlltier, Jean Gregoire, Michel Joyal, Jean-Claude Tardif, Montreal Heart 
Institute, Montreal, Quebec, Canada. 
Background.Balloon angioplasty (BA) induces an early inflammatory reaction and 
periprocedural CRP correlates with late restenosis.The aim of the current study was to 
charactertze the type and duration of inflammatory reaction after BA, and to identify more 
specific inflammatory markers correlating with restenosis. Methode.We studied 56 con- 
secutive patients (pts) with stable coronary artery disease who underwent successful BA. 
Blood was drawn just before BA. at l-month, and at 6.month follow-up. We evaluated 
CD40 ligand (sCD40L), vascular cell adhesion molecule-l (VCAM-1). and matrix metal- 
loproteinase-2 (MMP-2). All pts underwent 6-month follow-up angiography. Results. Lev- 
els of both sCD40L and MMP-2 increased from pm-PTCA to 1 month, and decreased 
between 1 month and 6 months (Table). Plasma levels of sCD40L at l-month correlated 
with angiographic late loss (r -0.46, p=O.OOl). A receiver operating characteristic (ROC) 
curve showed that sCD40L was a good predictor of 6-month dichotomous angiographic 
restenosis (area under curve 0.75. 95% Cl 0.61-0.68). with a cutpoint of 4.0 ngil or more 
having a sensitivity and specificity of 0.76 and 0.72. Conclusions. Our results imply that 
inflammation persists for at least 1 month after EA. This suggest that anti-inflammatory 
interventions to prevent restenosis should be active for more than 1 month post BA. The 
predictive value of sCD40L may indicate the relevance of this pathway as a therapeutic 
target for restenosis prevention. 
Serum Levels of Inflammatory Markers After BA 
sCD40L 
sMMP-2 
sVCAM-1 
hs-CRP 
pre-BA 1 month F-up 
4.1kO.6 5.6eO.6 
1133.6t36.6 1326.1i36.6 
995.2i67.3 1044.7+67. 
5.1+10.9 3.5i3.6 
6-month F-up 
4.2+0.6 
1163.1+38.6 
1064.7e67.5 
3.3t3.6 
p value 
p<o.o2 
<0.0001 
0.07 
“S 
1102-23 Slochemlcal Markers of Myocardlal Injury in Patients 
With Stable Anglna Pectoris Undergoing Successful 
PTCA: Clinical Importance? 
v, Jan Ravkilde, Dept. ofCardiology Skejby University Hospital, Aarhus, 
Denmark, Dept. of Cardio/ogy Aalborg University Hospital, Aalborg, Denmark. 
Objective To evaluate the importance of increases in biochemical markers in patients 
with stable angina pectorfs (SAP)undergoing successful elective (PTCA) concerning clin- 
ical usefulness and prognostic value 
Methods 544 consecutive patients with SAP undergoing elective successful PTCA 
according to ACCIAHA guidelines. We measured the concentration of CKMBmass. 
troponin T (TnT). 3 different troponin I’s and CKMB and CKtotal activity. Bloodsampling 
prePTCA, 6 and 16 hours after PTCA. 
Results Number of stenoses treated per patient median 1.45 (range l-4). Biochemical 
marker positive and median (range) as given in the table. At 1 month the total events 
were 1.6% (g/544). all nine events were UAP. At 3 months the total events were 3.7 % 
(20/544) with 2 cardiac death, 1 AMI. 17 UAP. At 6 months the total events were 
increased to 6.1 % with 3 cardiac deaths, 3 AMI, 27 UAP. 
Events % (cardiac death, AYl,mPTCA, 
CABG,raadm.UAP) 
1 month tmonths Gmonths 
Marker cut-off Positive Positive negatwe Positive negstbve Positive negative 
VSIUSS >(median 
(range)) 
CKMBma 10.0 ng/ 6.6% 4,2 1,4 12,5” 28 20.1” 4,6 
ss mL (27.5 (10.4-114)) 
TnT 0.10 ng/ 6.5% 2,2 I,6 10,9 3,O 19,6” 4,6 
mL (0.26 
(0.1 -3 06)) 
Tfll- 0.5 nq/rnL 15.7% 1,2 I,6 I,2 3.1 11,9’ 5,1 
Beckm. (1.09 (0.54-100)) 
Tnl-Ortho 1 .O nglmL 6.8% 2,i 1,6 8,5# 3.2 17,O” 5,l 
(2.19(1.01-100)) 
T&Dade 1.5 ng/mL 10.1% 1.9 I,7 9.3’ 3.1 16,7” 5,0 
(1.6 (1.5-37.8)) 
CK 2w U/L 4.5% 4,2 1.6 16,6’ 3,6 25.0” 5,3 
(314 (209.966)) 
CKMBact 24 3.3% 5,6 1,5 16.7’ 3,3 27,7- 5,4 
U/L (62 
(30 - 122)) 
‘PC 0.05 , **p <O.Ol % p=o.o9 
Conclusion The incidence of CKMBmass and troponin is app. 10%. At 3 and 6 months 
follow-up CKMBmass, TnT, Tnl-D, CK and CKMBcat. markerpositive patients had a sig 
nificant increased risk of UAP and repeated revascularfsation. however the figures for 
deaths and AMI’s were low. 
1102-24 Myocsrdial Necrosis Is Halved in Patients Undergoing 
Elective Percutaneous Coronary lnterventlon Who Are 
Pretreated With Lipid-Lowering Therapy 
Herbelt D. AmI Martin J. Quinn, Hitinder S. Gurm, Eric J. Topol, Michael Llncoff, 
Danielle M. Brennan, Michael S. Lauer, Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: Myccardial necrosis occurs commonly after percutaneous coronary inter- 
vention (PCI) and has been associated with increased long-term morbidity and mortality. 
Lipid-lowering agents (LLA) exert multiple effects that might reduce the incidence of myo- 
cardial necrosis after PCI, including plaque stabilization, inhibition of platelet thrombus 
formation and improvement in endothelial function. Nevertheless, it is not known whether 
LLA treatment before PCI is associated with less subsequent myocardial necrosis. 
Methods: We compared the incidence of myocardiat necrosis after elective PCI among 
patients in the EPIC trial who were (n=155) or were not 61~706) on a LLA prior to their 
procedure. A propensity analysis was used to match patients on the probability of treat- 
ment with a LLA prior to their PCI. 
Results: Overall, 16% of patients had post-procedure myocardial necrosis (CK-MB >= 3X 
ULN). LLA pm-treatment was associated with significantly less myocardial necrosis (9 
vs. 17%, Risk Ratio [RR] = 0.49, 95% Cl 0.26-0.62. p=O.O06) [Figure]. After adjusting for 
other potential confounders and the propensity score, LLA pre-treatment was associated 
with significantly less myocardial necrosis (RR = 0.51, 95% Cl 0.25-0.97) p = 0.039). 
Conclusion: Myocardial necrosis was half as likely when patients were on a LLA before 
elective PCI. Randomized data would help determine whether elective PCI should be 
deferred until after the initiation of lipid-lowering therapy. 
p-O.37 
3s- s’;1 
30 - 
26 - 
p = 0.01 
n p-O.05 
E so- 
: 
17 n 
$ 15- 13 
P 
s_cx FI 
10 _ II 
4 5. 
1102-25 Effect of Pre-Procedure Lipid Lowering Therapy on In 
Hospital Mortality Following Percutaneous Coronary 
Interventions: An Analysis of a Large Multicenter 
Database 
Mauro Moscucci, Eva Kline-Rogers, Anthony C. DeFranco, Mictrael D’D~QCI& Ann 
Maxwell-Eward, David Share, John G. McGinnity, Michele De Gregorio, William L. 
Meengs. Vivien L. Clark, Kim A. Eagle, For The Blue Cross Blue Shield of Michigan 
Cardiovascular Consortium (BMCP), University of Michigan, Ann Arbor. Michigan. 
Background: Recent studies have shown a reduction in early mortality in patients with 
acute coronary syndromes discharged home on lipid lowering therapy. The objective of 
our study was to determine the potential effect of pre-procedure lipid lowering therapy 
with statins on in-hospital mortality in patients undergoing percutaneous coronary inter- 
ventions (PCI). 
Methods: We analyzed 16,932 PCI performed between July 1997 and September 2006 
in a consortium of 6 hospitals in Michigan. In-hospital mortality rates in patients who were 
on lipid lowering therapy before the procedure (n=9,064) were compared with those of 
patients who were not (n=7,646). The effect of pre-procedure lipid lowering therapy was 
analyzed using multivariate logistic regression analysis. 
Results: The in-hospital mortality rate was 0.56% in the group of patients who were on 
lipid lowering therapy before the index procedure and 2.6% in the group of patients who 
were not (OR 0.2, 95% Cl 0.14-0.24, p<O.OOl). After adjustment for baseline comorbidi- 
ties, demographic variables, indication for the procedure, severity of underlying coronary 
disease, and for a propensity score for being on lipid lowering therapy, lipid lowering ther- 
apy remained a strong independent predictor of lower in-hospital mortality (Adjusted OR 
0.31, 95% Cl 0.27-0.44). 
Conolusfon: 1) Pm procedure lipid lowering therapy is associated with a significant 
reduction of in hospital mortality following PCI. 2) Although the possibility of bias from 
other unknown confounders cannot be excluded, the strong association between pre- 
procedure lipid lowering therapy and reduced mortality warrants further investigations in 
other registry and prospective studies. 
1102-26 Adrenomedullin as a Predictor of Restenosis and 
Antiintimal Proliferative Hormone in the Patients With 
Coronary Intervention 
BIkenouchi, Nanae Kada, Nobuhiko Itoh, Tokutada Satoh, Yoshiyuki Hada. 
Yasunobu Hirata, Kenji Kangawa. JR Tokyo General Hospital and University of Tokyo, 
Tokyo, Japan, National Cardiovascular Center. Osaka, Japan. 
[Background]: Adrenomedullin (AM) is a vasoactive hormone which is mainly produced in 
arterial endothelial cells especially in the coronary arterial system. It was reported that in 
patients with acute myocardial infarction and congestive heart failure, plasma AM was 
increased. It was also revealed that AM inhibits proliferation and migration of vascular 
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smooth muscle cells. The aim of the present study is to investigate roles of AM in 
patients with coronary altery disease (CAD). [Methods]: Plasma AM concentrations from 
the femoral vein and coronary sinus were measured before and after coronary interven- 
tion in 41 patients with CAD (35 males, 6 females, 66+6y/o. mean+SD: POBA 17, stents 
24). Patients included 20% of family histoty of CAD, OMI 30%, DM 35%, smoker 50%, 
hyperlipidemia 63%, and HT 66%. Relations among plasma AM and various coronary 
risk factors were analyzed.[Results]: Baseline AM was higher in patients with the greater 
diameter of stenotic vessels. Neither insertion of introducer sheaths nor diagnostic cathe- 
terization influenced the plasma AM. Coronary interventions increased plasma AM signif- 
icantly in both POBA and stent group (10.7+3.2 vs. 12.6+4.5 fmollml, n=41,p<0.0001). 
Coronary sinus blood sampling showed greater increase of plasma AM compared to the 
systemic vein (+28% vs. +14%). The presence of hyperlipidemia. larger target vessel 
size and smaller number of diseased vessels were also significantly correlated with the 
more increase in plasma AM by the intewention. In the restenosis group, baseline 
plasma AM was significantly lower compared to the non-restenosis group (6.6+1.4 vs. 
11+3.4 fmollml, ~~0.05). Among other factors, CRP was higher in the restenosis group 
(0.32+0.15 vs. 0.16+0.10, p<O.Ol). In the hyper lipidemia group, patients with the higher 
AM (~15 fmollml) showed the lower restenosis rate (17%) compared to the patients with 
the lower AM (>15 fmollml) group (50%). [Conclusions]: Plasma adrenomedullin was 
increased by coronary interventions. Plasma AM was higher in non-restenosis group. 
These results suggest that AM could be one of predictors for restenosis, and AM may 
play a role to suppress restenosis, at least In part, in CAD patients with coronary inter- 
vention. 
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1103-3 Time Course of Transcardiac Interleukin-6 Release After 
Coronary Stenting for Stable Angina 
Joelle Kefer, Laurence M. Galanti, vE. University of Louvain, Brussels, 
Belgium. 
Background: Increases in circulating levels of interleukin-6 (IL-6) and C-reactive protein 
(CRP) have been reported after coronary balloon angioplasty, particularly in the context 
of unstable coronary syndromes. These changes could reflect inflammatory reactions 
within the coronary vasculature related to plaque unstability or to procedure-related vas- 
cular damage. 
Methods: To further investigate the influence of vascular trauma induced by stent implan- 
tation on the release of these inflammatory markers in patients with stable angina, we 
measured aortic and coronary sinus (CS) concentrations of IL-6 and CRP before, imme- 
diately and 2 hours after elective stent implantation in the proximal segment of the LAD in 
6 patients. 
Results: Before stenting, IL-6 concentrations were similar in CS and in aorta (3.049.32 
and 3.06?2.36 pg/ml; NS), the IL-6 CS/Aorta ratio averaging 0.99fo.12. Immediately and 
2 hours after stenting, the IL-6 CSlAorta ratio increased respectively to 1.1310.11 and to 
1.40x).61 (both pcO.04 vs before stenting) reflecting a significant transcardiac release: 
IL-6 concentrations increased in the CS to 3.15&?.42pg/ml (NS) immediately after and to 
7.99i4.71pgIml (p<O.Ol) 2 hours after stent implantation. CRP concentrations averaged 
3.10~.35mg/l in the aorta and 3.16t3.49 mgil in the CS before stenting and did not 
change during the study (respectively 4.3lk4.19 and 3.37+3.75 mg/l 2 hours after stent- 
Ing ; NS). 
Conclusions: Elective coronary stenting for stable angina results in a significant transcar- 
disc release of IL-6 detectable up to 2 hours after the procedure. 
1103-4 Age Dependent Impact of the 694 TT Genotype of the 
Endothelial Nitric Oxide Synthase on the Outcome in 
Men Following Coronary Stent Placement 
Olaa Gorchakova, Werner Koch, Nicolas van Beckerath. Julinda Mehilli. Angela 
Ehrenhaft, Albert Schbmig, Adnan Kastrati. Deutsches Herzzenfrum, Munich, Germany 
1. Med. Klinik rechts der Tsar, Munich, Germany 
Background: The functional 694Gn endothelial nitric oxide synthase (eNOS) polymor- 
phism has been found to be clinically relevant, with TT genotype as a risk factor. Since 
the relative contribution of genetic factors may decrease with age and may be more pro- 
nounced among younger men, we performed a specific analysis of male patients with 
coronary artery disease undergoing coronary stenting. 
Methods: We analyzed 1459 consecutive men; there were 639 patients < 60 years and 
620 patients 2 60 years. One-year mortality was the primacy endpoint of the study. The 
combined l-year incidence of death and myocardial infarction (Ml) was also assessed. 
Odds ratios (OR) and respective 95% confidence intelvats associated with carriage of 
the 694TT eNOS genotype are shown. 
Results: The 694TT eNOS genotype was associated with a significant risk increase for 
death at 1 year only among younger patients (figure). In patients < 60 years, the mortality 
was 5.7% in TT-carriers vs 0.9% in G-allele carriers (OR, 6.4 [2.t to 20.11, P=O.OOl). The 
difference was much less evident in patients t 60 years, with a mortality of 6% in n-car- 
riers and 3% In G-allele carriers (OR, 1.9 [0.77 to 5.101, P=O.2). The same was also true 
for the combined incidence of death and Ml at 1 year. When TT-carriers were compared 
to G-allele CSrriSrS. it was 6.6% vs 2.6% (P=O.O07) for younger men and 7.2% vs 4.3% in 
older men (P=O.3). 
Conclusions: The 694ll genotype can serve as a prognostic marker of an unfavorable 
outcome aner coronaiy stenting, especially among young men. 
1103-5 Accelerated Atherosclerotic Change in Saphenous Vein 
Bypass Graft Restenosis: Importance of the Lipid Core 
&eno S. Pess&& Andrew Farb, Deena K. Weber, Allen P. Burke, Renu Vinani. 
Armed Forces Institute of Pathology, Washington, Dw. of Columbia. 
Background: Advanced saphenous vein graft (SVG) plaques have ~30% larger lipid 
core content than plaques in native coronary arteries (CA’s). While stenting of SVG’s is 
superior to PTCA, SVG stent restenosis rates remain high. Despite the increased use of 
SVG stents, their morphologic features, the mechanism of atheroembolization, and the 
predictors of SVG stent restenosis are incompletely understood. 
Methods: Histology was performed on 16 stented SVG’s, implanted 290 days, from 13 
patients. A histologic success was defined as a stent area stenosis of 250% and resteno- 
sis as a stent stenosis of >50%. 
Results: Lipid core penetration (LCP) by the stent deep within the plaque was present in 
50% of cases, a nearly 2.fold increased frequency of LCP that is seen in native coronary 
artery stenting. Further, 75% of stents with lipid core penetration showed in-stent rest- 
enosis (vs. 25% without LCP, p<O.O5). LCP by the stent was associated with increased 
neointimal growth (Table). The neointima in restenotic segments showed smooth muscle 
cells admixed with fibrin and foamy macrophages. consistent with early atherosclerotic 
change and distinctive from restenosis lesions in native CA’s, 
Conclusions: Stenting of atherosclerotic SVG’s frequently results in lipid core panetra- 
tion by the stent, which accounts for acute atheroembolization and is associated with 
enhanced neointimal growth. Accelerated atherosclerosis is present in SVG in-stent rest- 
enosls, a morphology that differs from stent neointima in native CA’s, 
Stent neointima (NI) measurements 
NI Area (mm2) NI Thickness (mm) O/&tent Stenosis 
LCP Present 
LCP Absent 
P 
6.4i2.4 
2.4+1.0 
co.oOO1 
0.62+0.37 62i14 
0.25&plusmn;0.10 37221 
<O.OOl 0.02 
1103-6 Apolipoprotein E Genotype Predicts the Outcome After 
Coronary Artery Stenting 
Uem&Q&, Wolfgang Latz, Korinna Griesser, Nicolas van Beckerath, Angela 
Ehrenhaft, Julinda Mehilli, Marianne Eichinger, Albert Schbmig, Adnan Kastrati, 
Deutsches Herzzentrum Muenchen, Muenchen, Germany. 
Background: The T allele of the -219Gfl polymorphism and the ~4 allele of the gene 
encoding apolipoprotein E were found to be associated with susceptibility to coronary 
artery disease. We examined whether these alleles were also related to the risk of major 
adverse clinical events (MACE: death, myocardial infarction [Ml], target vessel revascu- 
larization [TVR]) aner coronary artery stenting. 
Methods: In 1650 consecutive patients with coronary artery disease, the occurrence of 
MACE was evaluated over 1 year after stent placement. Genotyping was based on the 
polymetase chain reaction and involved the TaqMan technique. 
Results: The frequencies of the -219T allele and the ~4 allele were 0.49 and 0.26, 
respectively. MI, TVR, and the combined incidence of MACE were significantly lower 
among carriers of the -219T allele compared to -219G allele carriers, with patients of 
genotype TT having the lowest risk (Table). In contrast, the risk of Ml, TVR or MACE was 
not found to be related to the ~4 allele (Table). 
-219GG -219GT -219TT P e4 none4 P 
Ml (%) 3.2 1.5 1.1 0.03 1.2 2.1 0.24 
TVR (%) 24.3 20.2 16.2 0.006 16.5 21 .o 0.24 
MACE (%) 26.1 23.2 18.2 0.01 20.3 23.6 0.14 
Conclusions: The apolipoprotein E genotype may serve as a prognostic marker of MI, 
TVR. and MACE after coronary artery stenting. The association is based on the presence 
of the -219T allele rather than the e4 allele. 
